CANNABINOID RECEPTOR EXPRESSION AND THE EFFECT OF OLORINAB, A PERIPHERALLY ACTING, HIGHLY SELECTIVE, FULL AGONIST OF THE CANNABINOID RECEPTOR 2 (CB2), IN RODENTS WITH COLITIS AND CHRONIC VISCERAL HYPERSENSITIVITY

被引：0
|
作者：
Castro, Joel
Maddern, Jessica
Garcia-Caraballo, Sonia
Schober, Gudrun
Lindstrom, Beatriz
Schmiel, Shirdi
Brierley, Stuart
机构：
来源：
GASTROENTEROLOGY | 2020年 / 158卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1078
引用
收藏
页码：S269 / S269
页数：1
相关论文
共 50 条
  • [21] A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies
    Chicca, Andrea
    Batora, Daniel
    Ullmer, Christoph
    Caruso, Antonello
    Gruner, Sabine
    Fingerle, Ju''rgen
    Hartung, Thomas
    Degen, Roland
    Mueller, Matthias
    Grether, Uwe
    Pacher, Pal
    Gertsch, Jurg
    ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2024, 7 (08) : 2424 - 2438
  • [22] Targeting the cannabinoid CB2 receptor:: Mutations, modeling and development of CB2 selective ligands
    Raitio, KH
    Salo, OMH
    Nevalainen, T
    Poso, A
    Järvinen, T
    CURRENT MEDICINAL CHEMISTRY, 2005, 12 (10) : 1217 - 1237
  • [23] Targeting the CB2 cannabinoid receptor in osteoporosis
    Bab, Itai
    Ofek, Orr
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2011, 6 (02) : 135 - 138
  • [24] OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE AGONIST OF THE CANNABINOID RECEPTOR TYPE 2 FOR THE MANAGEMENT OF VISCERAL PAIN IN INFLAMMATORY BOWEL DISEASE (IBD) - PRECLINICAL AND EARLY CLINICAL DEVELOPMENT
    Lindstrom, Beatriz F.
    Ruckle, Jon L.
    Turner, Stewart A.
    Stauber, Kathe
    Brierley, Stuart M.
    English, Brett A.
    Yacyshyn, Bruce
    INFLAMMATORY BOWEL DISEASES, 2019, 25 : S64 - S64
  • [25] Evaluating signaling bias for synthetic cannabinoid receptor agonists at the cannabinoid CB2 receptor
    Patel, Monica
    Grimsey, Natasha L.
    Banister, Samuel D.
    Finlay, David B.
    Glass, Michelle
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (06):
  • [26] Recent advances in the development of selective ligands for the cannabinoid CB2 receptor
    Marriott, Karla-Sue C.
    Huffman, John W.
    CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2008, 8 (03) : 187 - 204
  • [27] Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists
    Han, Sangdon
    Thatte, Jayant
    Buzard, Daniel J.
    Jones, Robert M.
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (21) : 8224 - 8256
  • [28] Novel azoles as potent and selective cannabinoid CB2 receptor agonists
    Harnett, Jeremiah J.
    Dolo, Christine
    Viossat, Isabelle
    Auger, Florence
    Ferrandis, Eric
    Bigg, Dennis
    Auguet, Michel
    Auvin, Serge
    Chabrier, Pierre-E.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (01) : 88 - 91
  • [29] Involvement of cannabinoid CB2 receptor-mediated response and efficacy of cannabinoid CB2 receptor inverse agonist, JTE-907, in cutaneous inflammation in mice
    Ueda, Y
    Miyagawa, N
    Matsui, T
    Kaya, T
    Wamura, H
    Iwamura, H
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2005, 520 (1-3) : 164 - 171
  • [30] SAFETY AND EFFICACY OF OLORINAB, A PERIPHERALLY RESTRICTED, HIGHLY SELECTIVE, CANNABINOID RECEPTOR 2 AGONIST IN A PHASE 2A STUDY IN CHRONIC ABDOMINAL PAIN ASSOCIATED WITH CROHN'S DISEASE
    Yacyshyn, Bruce
    Ginsberg, Daniel C.
    Gilder, Kye
    Walsh, Brandon
    English, Brett
    Turner, Stewart A.
    Klassen, Preston
    Hanauer, Stephen B.
    Barish, Charles F.
    Higgins, Peter D.
    GASTROENTEROLOGY, 2019, 156 (06) : S665 - S665
12345